exemestane; tamoxifen citrate
RANDOMIZED PHASE II STUDY IN FIRST LINE HORMONAL TREATMENT FOR METASTATIC BREAST CANCER WITH EXEMESTANE OR TAMOXIFEN IN POSTMENOPAUSAL PATIENTS
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00002777/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 342 чел. во всех странах исследования.
- Центров в реестре: 2 в 2 городах. Список — ниже на странице.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–2
- Биомаркеры в критерияхГормональные рецепторы (ER/PR)
- Стадияметастатическая (IV)
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 76
Критерии включения
- DISEASE CHARACTERISTICS:
- Histologically or cytologically proven adenocarcinoma of the breast that is metastatic and progressive or locally recurrent and inoperable
- At least one bidimensionally measurable or evaluable lesion
- Lytic bone lesions on x-ray/CT scan, surrounded by calcified bone, and at least 1 cm
- Bidimensionally measurable extraosseous disease required for patients on bisphosphonates
- The following are not considered evaluable:
- Previously irradiated lesions
- Lymphangitic spread
- Ascites
- Blastic bone lesions
- Pleural effusions
- No rapidly progressive disease for which hormonal therapy is not indicated
- No massive visceral disease (i.e., more than one third of any organ)
- No brain metastases
- Hormone receptor status:
- Estrogen receptor positive or progesterone receptor positive, defined by 1 of the following:
- At least 10 femtomoles H3-estrogen or at least 20 femtomoles
- H3 progesterone binding per mg of cytosol protein by DCC or sucrose density method
- At least 0.10 femtomoles H3-estrogen or at least 0.20 femtomoles
- H3-progesterone binding per mg of DNA by IF/EIA technique
- Positive immunohistochemistry noted on pathology report
- Unknown receptor status eligible provided:
- Disease-free interval of at least 2 years since adjuvant therapy or initial surgery (if no adjuvant therapy), including most recently treated tumor in bilateral breast cancer if status unknown in one primary tumor
- PATIENT CHARACTERISTICS:
- Age:
- 18 and over
- Sex:
- Female
- Menopausal status:
- Postmenopausal by 1 of the following:
- Natural menopause and more than 1 year since last menstrual period (LMP)
- Radiation-induced oophorectomy and more than 1 year since LMP
- Chemotherapy induced menopause if:
- At least 1 year since LMP (+ 1 year post-tamoxifen)
- Serum FSH and LH and plasma estradiol levels in postmenopausal range
- LHRH-induced amenorrhea
- Surgical castration
- Patients under age 56 with prior hysterectomy and 1 or both ovaries intact or tamoxifen-induced amenorrhea with at least 12 months since prior tamoxifen must have postmenopausal serum FSH and LH and plasma estradiol concentrations
- Performance status:
- ECOG (WHO) 0-2
- Hematopoietic:
- Absolute neutrophil count at least 1,500/mm\^3
- Platelet count at least 100,000/mm\^3
- Hepatic:
- Bilirubin less than 1.5 times upper limit of normal (ULN)
- SGOT/SGPT less than 2.5 times ULN (less than 5 times ULN with liver metastases)
- Renal:
- Creatinine less than 1.5 times ULN
- Cardiovascular:
- No deep venous thrombosis
- Other:
- No mental incapacitation
- No severe concurrent disease
- No prior or concurrent malignancy except curatively treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
- PRIOR CONCURRENT THERAPY:
- Biologic therapy:
- No concurrent immunotherapy
- Chemotherapy:
- See Disease Characteristics
- At least 3 weeks since chemotherapy for metastatic disease and recovered
- No more than 1 prior chemotherapy regimen for metastatic disease
- Prior adjuvant chemotherapy allowed if disease free for at least 6 months
- No concurrent chemotherapy
- Endocrine therapy:
- No prior hormonal therapy for advanced disease (e.g., tamoxifen or LHRH agonists)
- Prior adjuvant tamoxifen allowed if disease free for at least 6 months
- No other concurrent hormonal therapy, including steroids
- Radiotherapy:
- Recovered from toxic effects of prior radiotherapy
- Concurrent palliative radiotherapy, including whole brain irradiation, allowed
- Surgery:
- See Disease Characteristics
- No prior ovariectomy for advanced disease
- Other:
- No other concurrent investigational drugs
- Concurrent bisphosphonates allowed if short term (7 days) for hypercalcemia due to suspect tumor flare or if on prior bisphosphonates with bidimensionally measurable extraosseous lesion
Источник: ClinicalTrials.gov, NCT00002777 · запись обновлена в реестре 2 июля 2012.
Дизайн и результаты
Цель исследования
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen.
PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
Где проходит
2 центра в 2 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00002777 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.